2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1123

Comparison of Anatomic Knee Alignment On Physical Examination and Radiographs
Abstract Number: 129

Comparison of Automated, Computer-Based Assessment and Visually Assessed Disease Activity Scores in ICG-Enhanced Fluorescence Optical Imaging in Patients with Rheumatic Disorders: A Feasibility Study
Abstract Number: 1464

Comparison of Baseline Characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) Cohort to Patients Enrolled in Clinical Trials of Diffuse Systemic Sclerosis
Abstract Number: 1616

Comparison of Conventional and Wholebody Magnetic Resonance Imaging for Assessing Inflammation and Structural Damage in Psoriatic Arthritis and Axial Spondyloarthritis
Abstract Number: 53

Comparison of Decision Rules for Identifying Patients with Rheumatoid Arthritis (RA) in Administrative Healthcare Databases
Abstract Number: 495

Comparison of Discontinuation Rates by Biologic Since 1998 in US Patients with Rheumatoid Arthritis
Abstract Number: 1327

Comparison of Four Different Intensive Treatment Strategies in Patients with Early Rheumatoid Arthritis in Korea
Abstract Number: 695

Comparison of Intense Pulsed Light and Laser Treatment of Telangiectases in Systemic Sclerosis
Abstract Number: 2249

Comparison of Mycophenolate Mofetil and Intravenous Cyclophosphamide As Induction Therapy in Korean Patients with Lupus Nephritis
Abstract Number: 484

Comparison of Rheumatoid Arthritis-Related Health Care Resource Use and Comorbidities Among Patients with Rheumatoid Arthritis Treated with Adalimumab Vs. Etanercept
Abstract Number: 1359

Comparison of Sacroiliac MRI Evaluation Versus Sacroiliac x-Rays in Peripheral Psoriatic Arthritis: Evidence of Silent Disease and Lack of Association to HLA-B27
Abstract Number: 646

Comparison of the Lupusqol and SF-36 Scores As Valid Measures of Change in Health Related Quality of Life
Abstract Number: 1346

Comparison of Three Screening Tools in Psoriatic Arthritis: The Contest Study
Abstract Number: 500

Comparison of Tolerability Between Tumor Necrosis Factor-Inhibitors and Tocilizumab for the Treatment of Rheumatoid Arthritis
Abstract Number: 1913

Complete Tophus Response in Patients with Chronic Gout Initiating Pegloticase Treatment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].